This is a transformative reverse-merger for CMMB, which will deliver a ~$150M combined entity with $30M+ in new cash and a clear pipeline catalyst in RA. The merger provides a path to a Nasdaq listing as SCIP with institutional sponsorship. Monitor the shareholder vote, SEC S-4 filing, and Israeli tax ruling as near-term catalysts. The transition from CMMB to SCIP creates an event-driven opportunity for long-biased traders willing to hold through the Q4 2026 close window.
Drug in focus
CMMB drug pipeline →nebokitug
◆ Mixed Named in this 6-K- Impact
- Phase
- Phase 2 (complete); preparing Phase 3
- Time to market
- At least 4-6 years; Phase 3 PSC trial not yet initiated, and even if successful, filing and approval would follow several years later. The new RA program is even earlier-stage.
- Next catalyst
- None dated
What to watchThe just-announced merger with Scipher Medicine (all-stock, closing Q4 2026) reshapes the investment thesis: pre-merger Chemomab holders get ~32% of the combined entity plus CVRs tied to nebokitug milestones, while the new company will run an AI-guided Phase 2 RA trial. Watch for Phase 3 PSC trial financing clarity post-merger and the merger close vote. The stock already ran ~80% into the deal, much of the near-term re-rating may be priced in.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 8 $1.97entry
- T+1 · 4mo ago −7.11%α −7.95% · $1.83
- T+5 · 4mo ago −22.34%α −23.20% · $1.53
- T+20 · 3mo ago −11.17%α −14.44% · $1.75
- T+60 · 7w ago −39.59%α −41.91% · $1.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Chemomab Therapeutics (CMMB) entered into a definitive merger agreement to be acquired by Scipher Medicine Corporation, a precision medicine company. The combined company, valued at $150 million, will operate as Scipher Medicine Corporation and trade under the ticker SCIP. Chemomab shareholders will own approximately 32% of the combined company before a concurrent $30 million PIPE. The merger is expected to close in Q4 2026.
Key Facts
- Combined company pre-money valuation of $150 million ($48 million for Chemomab, $102 million for Scipher, subject to adjustment for Scipher's indebtedness)
- Chemomab equity holders expected to own approximately 32% of combined company; Scipher equity holders approximately 68%, pre-PIPE
- Concurrent PIPE investment of not less than $30 million from a syndicate led by Northpond Ventures including Khosla Ventures, Blue Owl Healthcare Opportunities, and funds managed by Neuberger
- Post-merger company to focus on advancing nebokitug into a Phase 2 RA trial with AI-powered precision medicine enrollment using Scipher's PrismRA test
- Phase 2 RA readout expected H1 2028; cash runway expected into H2 2028
- Chemomab pre-merger shareholders to receive CVRs for cash payments upon achievement of nebokitug milestones
- Merger expected to close in Q4 2026; combined company to trade under ticker SCIP on Nasdaq
Financial Impact
Combined company valued at $150 million pre-PIPE; Chemomab valued at $48 million, Scipher at $102 million (subject to adjustment for Scipher's indebtedness). Concurrent PIPE of at least $30 million at a valuation of $150 million with 100% warrant coverage at 50% of the PIPE valuation.
Risk Factors
- Transaction may not close due to failure of shareholder approval, regulatory hurdles, or failure to obtain Israeli tax rulings: $2M termination fee payable by Chemomab to Scipher in certain events
- Chemomab must have Net Cash of at least $0 at closing; no Indebtedness
- Phase 2 RA data readout not expected until H1 2028, several years away
- Lock-up agreements restrict selling by key Chemomab and Scipher insiders after closing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003442 |
| Exhibit: exhibit_99-1.htm | 0001178913-26-003442 |
| Document: zk2635653.htm | 0001178913-26-003442 |
| Document: 0001178913-26-003442-index-headers.html | 0001178913-26-003442 |
| Document: 0001178913-26-003442-index.html | 0001178913-26-003442 |
| Document: 0001178913-26-003442.txt | 0001178913-26-003442 |
Track record
15 reports on CMMB
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
- Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
- Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
- Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
- Jul 8, 202618w ago 6-K Bullish 7/10 Viewing Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers